poisar

Stocks · News reference

Thermo Fisher Stock Hits Record High: What's Happening?

Evette Mitkov

Thermo Fisher is rising Thursday, hitting an all-time high as strong Q2 results and raised FY guidance continue to support momentum.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TMO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Global Automated and Closed Cell Therapy Processing Systems Market Set for Expansion as Scalable Workflows Drive Growth, 2026-2033

    The global automated and closed cell therapy processing systems market is projected to reach USD 7.0 billion by 2033, expanding at a CAGR of 20.2%. Growth is driven by increasing investment in regenerative medicine, CAR-T cell therapies, and personalized medicine. Non-stem cell therapy leads the type segment, while pre-commercial/R&D-scale applications dominate by scale. North America leads regionally, with LAMEA posting the fastest regional growth at 21.6% CAGR.

    TMOSSSGYLZAGY
  2. Researchandmarkets.Com

    Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand

    The global biosimulation market reached USD 4.09 billion in 2025 and is projected to grow at 16.90% CAGR through 2035, reaching USD 19.49 billion. Growth is driven by AI-driven drug discovery, virtual clinical trials, personalized medicine demand, and computational modeling adoption. However, geopolitical instability in the Middle East has created near-term supply chain disruptions and increased pharmaceutical packaging costs by 15-20%. Key players are pursuing strategic acquisitions and platform launches to expand capabilities.

    CERTSLPSDGRTMO
  3. Delveinsight

    Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

    The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.

    RHHBYQTRXABTTMOSMMNY